Meningococemia durante el tratamiento con eculizumab-Reference-Cited by-同舟云学术

Meningococemia durante el tratamiento con eculizumab

Published:2013-01 Issue:1 Volume:31 Page:62
ISSN:0213-005X
Container-title:Enfermedades Infecciosas y Microbiología Clínica
language:es
Short-container-title:Enfermedades Infecciosas y Microbiología Clínica

Author:

Rey-Múgica María de la Asunción,Hernando-Real Susana,Carrero-González Pablo,Queizán-Hernández José A.

Publisher

Elsevier BV

Subject

Microbiology (medical)

Reference6 articles.

1. Infección meningocócica probable en paciente con hemoglobinuria paroxística nocturna y tratamiento con eculizumab;Algado;Enferm Infecc Microbiol Clin,2012

2. Tratamiento de la hemoglobinuria paroxística nocturna con eculizumab: experiencia en España;López Rubio;Med Clin (Barc),2011

3. Eculizumab [consultado 12 Abr 2012]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000791/WC500054208.pdf

4. Diagnosis and treatment of nocturnal paroxismal hemoglobinuria;Urbano-Ispizua;Med Clin (Barc),2011

5. Vacunación del paciente con hemoglobinuria paroxística nocturna en tratamiento con eculizumab;Rodríguez-García;Med Clin (Barc),2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases;Infectious Disease Clinics of North America;2020-06

2. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors);Clinical Microbiology and Infection;2018-06

3. Infections associated with the use of eculizumab;Current Opinion in Infectious Diseases;2016-08

4. Eculizumab;Reactions Weekly;2015-04